SPY319.40+8.04 2.58%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

HC Wainwright & Co. Reiterates Neutral on Nektar Therapeutics, Lowers Price Target to $26

HC Wainwright & Co. reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $32 to $26.

Benzinga · 05/12/2020 11:09

HC Wainwright & Co. reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $32 to $26.